TTK Inhibitors as a Targeted Therapy for CTNNB1 (b-catenin) Mutant Cancers

Guido J.R. Zaman, Jeroen A.D.M. de Roos, Marion A.A. Libouban, Martine B.W. Prinsen, Jos de Man, Rogier C. Buijsman, and Joost C.M. Uitdehaag. Molecular Cancer Therapeutics. 2017